Title:
N-CARBOXAMIDOPYRAZOLINE DERIVATIVE SERVING AS P2X3 RECEPTOR ANTAGONIST AND APPLICATIONS
Document Type and Number:
WIPO Patent Application WO/2022/028154
Kind Code:
A1
Abstract:
An N-carboxamidopyrazoline derivative, provided with the compound of formula (I) or an enantiomer, a diastereomer, an epimer, and a racemate of same, or a pharmaceutically acceptable salt thereof. The compound is an antagonist of ligand-gated nonselective cation channel receptor subtype P2X3, and is applicable in treating or preventing various diseases mediated by P2X3 receptors.
More Like This:
| JP4405088 | New Thyroid Receptor Ligand and Method II |
| JPS58210012 | ANTIDIARRHEAL |
| JP2506263 | NEW BENZIMIDAZOLE COMPOUND |
Inventors:
CHENG YUNFENG (CN)
ZHU XINQIANG (CN)
ZHU XINQIANG (CN)
Application Number:
PCT/CN2021/103402
Publication Date:
February 10, 2022
Filing Date:
June 30, 2021
Export Citation:
Assignee:
HANGZHOU WESTAN PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
A61K31/415; C07D231/06; A61K31/4155; A61P11/00; A61P11/06; A61P11/14; A61P17/00; A61P17/04; A61P25/04; A61P25/06; A61P29/00; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D403/14; C07D405/14; C07D413/04; C07D413/14
Domestic Patent References:
| WO2009058298A1 | 2009-05-07 | |||
| WO2010111059A1 | 2010-09-30 | |||
| WO2018111738A1 | 2018-06-21 |
Foreign References:
| CN111892585A | 2020-11-06 | |||
| CN101282972A | 2008-10-08 | |||
| US5798311A | 1998-08-25 | |||
| EP0294666A2 | 1988-12-14 | |||
| EP0466408A1 | 1992-01-15 |
Other References:
LEWIS, C ET AL., NATURE, 1995, pages 432
JACOBSON ET AL., NEUROPHARMACOLOGY, 2016, pages 31
COCKAYNE DA ET AL., NATURE, 2000, pages 1011
PIJACKS W ET AL., NATURE MEDICINE, 2016, pages 1151
GAO XF ET AL., NATURE COMMUNICATION, 2015, pages 7650
CHAURET, N. ET AL., 49TH ANNUAL ESDR MEETING, 2019
ABDULQAWI R ET AL., EUR RESPIR J, 2013, pages 42
ABDULQAWI R ET AL., LANCET, 2015, pages 1198
MUCCINO D ET AL., PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 56, 2019, pages 56 - 62
COCKAYNE, D.A. ET AL., J. PHYSIOL., 2005, pages 621
WANG ET AL., PROC NATL ACADSCI USA, vol. 115, no. 19, 2018, pages 4939 - 4944
ZHONG ET AL., J BIOMOLSTRUCTDYN, vol. 35, no. 13, 2017, pages 2853
See also references of EP 4079725A4
JACOBSON ET AL., NEUROPHARMACOLOGY, 2016, pages 31
COCKAYNE DA ET AL., NATURE, 2000, pages 1011
PIJACKS W ET AL., NATURE MEDICINE, 2016, pages 1151
GAO XF ET AL., NATURE COMMUNICATION, 2015, pages 7650
CHAURET, N. ET AL., 49TH ANNUAL ESDR MEETING, 2019
ABDULQAWI R ET AL., EUR RESPIR J, 2013, pages 42
ABDULQAWI R ET AL., LANCET, 2015, pages 1198
MUCCINO D ET AL., PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 56, 2019, pages 56 - 62
COCKAYNE, D.A. ET AL., J. PHYSIOL., 2005, pages 621
WANG ET AL., PROC NATL ACADSCI USA, vol. 115, no. 19, 2018, pages 4939 - 4944
ZHONG ET AL., J BIOMOLSTRUCTDYN, vol. 35, no. 13, 2017, pages 2853
See also references of EP 4079725A4
Attorney, Agent or Firm:
HANGZHOU ZHIXIAN PATENT AGENCY (CN)
Download PDF: